May pag-asa na! COVID-19 vaccine from Pfizer and BioNTech shows potential in human trial


It has been reported that the vaccine being created by pharmaceutical giant Pfizer and biotech firm BioNTech showed positive results in early study.

We learned that the COVID-19 vaccine being developed has shown potential in human trial.

In a report by the Reuters (authored by Ludwig Burger and Patricia Weiss), the potential vaccine is the fourth early-stage COVID-19 vaccine that showed promising results in human testing.

The researchers discovered that the vaccine generated antibodies against the coronavirus in all of the 45 patients by 28 days after receiving a single injection.

"These preliminary data are encouraging, showing that BNT162b1 which exploits RBD SARS-CoV-2 as a target antigen is able to produce neutralizing antibody responses in humans at or above the levels observed in convalescent sera – and that it does so at relatively low dose levels. We look forward to providing further data updates on BNT162b1," Dr. Ugur Sahin, CEO and co-founder of BioNTech said.

However, double or higher doses of the said potential vaccine caused fever and other side effects. It is also not yet proven if higher antibody levels will give immunity against the coronavirus.

As reported by the CNBC (authored by Matthew Herper), in order to prove the immunity, Pfizer needs to conduct larger studies that aims to show that 50% of the people who received the vaccine will not be infected.

According to the World Health Organization (WHO), there are currently 17 coronavirus disease vaccines that are being developed and in clinical evaluation across the globe.

WHO director-general Tedros Adhanom Ghebreyesus claimed that an “effective” vaccine for COVID-19 is still uncertain for now.

Meanwhile, scientists claimed that the first “life-saving” medicine against the COVID-19 has been found.